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S U M M A R Y
Objectives: Japanese encephalitis (JE) is a devastating disease with high rates of death and disability that
occurs particularly in resource-limited, rural regions of Asia. Simple, accurate and inexpensive
diagnostics tests are vital for quantifying the burden of illness. This ﬁeld study evaluated two
commercial JE immunoglobulin M antibody capture (MAC) ELISA kits using samples from routine JE
surveillance.
Methods: Positive (n = 132) and negative (n = 218) sera were randomly selected from patient samples
collected as part of JE surveillance in Nepal in 2005. Samples were tested in a national public health
laboratory with commercial kits produced by XCyton and Inverness (Panbio). Results were compared
with those of the research lab-based reference standard, the Armed Forces Research Institute of Medical
Sciences JE MAC ELISA.
Results: Positive and negative predictive values and 95% conﬁdence intervals were 90% (82–95%) and
85% (79–89%) for Panbio1, 94% (88–98%) and 89% (87–93%) for Panbio2, and 84% (77–90%) and 96% (92–
98%) for XCyton kits, respectively. Sensitivities of Panbio1, Panbio2, and XCyton kits were 71% (63–79%),
80% (72–87%), and 93% (88–97%); speciﬁcities were 95% (91–98%), 97% (94–99%), and 89% (85–93%),
respectively. Overall percent agreement was 86% for Panbio1 and 91% for both Panbio2 and XCyton.
Conclusions: Both commercial kits had good predictive values when single serum samples from
encephalitis cases were tested in a national laboratory. Either kit can be used in similar JE-endemic
settings where co-transmission of dengue virus, a ﬂavivirus which has strong cross-reactivity with JE, is
limited. These results can inform decisions by countries and the World Health Organization laboratory
networks on national-level use of these kits for JE surveillance.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Japanese encephalitis (JE) virus is a mosquito-borne ﬂavivirus
and is the leading viral cause of childhood neurologic infection in
countries of the Asia-Paciﬁc region, including the Indian sub-
continent.1 In tropical regions where JE is endemic, transmission
generally occurs year-round, often with a peak during the rainy
season, but in temperate climates there may be seasonal patterns
of transmission and massive epidemics can occur.2,3 Besides the
high mortality due to JE, life-long disability from neurologic* Corresponding author. Tel.: +1 206 285 3500; fax: +1 206 285 6619.
E-mail address: akhalakdina@gmail.com (A. Khalakdina).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.11.020sequelae among 50% of survivors makes it an even more
devastating public health problem.2
Although up to 50 000 cases of JE and 10 000 deaths are reported
eachyear to theWorldHealthOrganization (WHO), theseﬁgures are
widely acknowledged to be underestimates of the true global
burden of disease.4 Approximately one-third of the world’s
population lives in areas of Asia that are endemic for JE. Although
some of these countries, including China, Japan, South Korea, Sri
Lanka, and Thailand have introduced JE immunization programs
resulting inadecline in JE incidence in these settingsover thepast20
years, the burdenof disease is still considerable in countrieswithout
access to vaccination. Applying a representative incidence rate of 2.5
per 10 000, as estimated from investigations using active case-
ﬁnding with laboratory conﬁrmation in a deﬁned population, to theses. Published by Elsevier Ltd. All rights reserved.
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intervention, therewouldbeapproximately175000cases peryear.4
A major reason for incomplete data on the incidence of JE is the
lack of adequate laboratory- and population-based surveillance in
many endemic countries. Even in countries that have functioning
surveillance systems for acute encephalitis syndrome (AES), there
is often limited availability of diagnostics and capacity to conduct
laboratory testing to conﬁrm the presence of JE virus (JEV)
infection. Diagnosis on clinical criteria alone is insufﬁcient to
distinguish JE from other etiologies of central nervous system
infection because JE symptoms are non-speciﬁc. A variety of
laboratory techniques are available for conﬁrmation of JEV
infection, but the WHO-recommended methodology for JE
surveillance purposes is demonstration of JE immunoglobulin M
(IgM) antibodies in blood and/or cerebrospinal ﬂuid (CSF).5
Several research institutions around the world have ‘in-house’
IgM antibody capture enzyme-linked immunosorbent assays (MAC
ELISAs), but some of these have shown variable performance when
used outside of the research laboratory and in ﬁeld laboratory
settings.6 Fortunately, in the past few years, commercial JE MAC
ELISA kits have become available. Commercial ELISA kits allow
convenient, standardized, and simpliﬁed testing at public health
laboratories and will thus improve and expand laboratory-based
surveillance for JE in endemic countries. Such quality-controlled
commercial assays for JE are a vital component of the WHO-
coordinated regional JE laboratory network.7
An evaluation of three newly available JE ELISA test kits was
undertaken in 2005 using a panel of well-characterized specimens.
About 30% of the panel comprised dengue-positive samples to
evaluate the issue of cross-reactivity between dengue and JE, two
closely related ﬂaviviruses.6 Although sensitivity was high, the
speciﬁcity of two of the kits was found to be low, presumably
because they do not have good capacity to distinguish between
dengue virus and JEV infections. Dengue virus infection can cause
neurological disease, and there is also the possibility that a patient
presenting with AES caused by a different pathogen could have
concurrent asymptomatic dengue virus infection with IgM in
serum.8 However, the composition of the sample panel was
artiﬁcially high for dengue in that it is unlikely that dengue IgM
would be present in the serum of 30% of patients tested during
routine AES surveillance.9,10 Therefore, further evaluation of these
kits was needed, in particular to determine the positive predictive
value, when testing samples collected from patients presenting
with symptoms compatible with encephalitis (i.e., in a real-world
clinical setting).
The objective of the current study was to evaluate the
diagnostic accuracy, speciﬁcally the predictive values, of two of
the commercial JEMAC ELISA kits evaluated in the 2005 study – the
JEV-Chex kit (manufactured by XCyton Diagnostics Ltd, India) and
the Panbio JE-dengue IgM combo ELISA kit (manufactured by
Inverness Medical Innovations (formerly Panbio Ltd), Australia) –
using samples collected during routine encephalitis surveillance in
Nepal.11,12 Nepal has been tracking cases of encephalitis since
1978, and in 2004 a laboratory-based surveillance system for JE
was established using the extensive acute ﬂaccid paralysis/polio
surveillance network.13 For JE surveillance, medical ofﬁcers
identify cases on the basis of a standard WHO clinical case
deﬁnition for AES5 and collect at least one serum sample for
diagnostic testing. An AES case is deﬁned as a person of any age, at
any time of year, with an acute onset of fever, a deterioration in
mental status (e.g., confusion, disorientation, coma, or inability to
talk), and/or new onset of seizures excluding simple febrile
seizures.14 An assay produced by the Department of Virology, US
Army Medical Component–Armed Forces Research Institute of
Medical Sciences (AFRIMS), was used as the reference standard.
AFRIMS is a recognized regional reference laboratory for Asia and isa designated WHO Collaborating Center. The AFRIMS, kit was the
reference standard used in the previous 2005 study.
2. Methods
2.1. Study population
Samples for this retrospective study were randomly selected
from among AES cases in 2005 for whom serum specimens were
available in the sample archives, stored at 20 8C after initial
testing. The Nepal AES surveillance samples were transported
under cold-chain conditions for testing with the AFRIMS ELISA at
one of two designated laboratories: the National Public Health
Laboratory (NPHL) of the Department of Health Services and the B.
P. Koirala Institute of Health Sciences in Dharan. All surveillance
samples collected and tested during 2005 (based on the result of
AFRIMS JE IgM ELISA testing performed at NPHL) were randomized
by technicians at the Walter Reed/AFRIMS Research Unit Nepal
(WARUN). A randomized list was generated of all archived serum
samples of AES cases from 2005 JE surveillance (both JE IgM-
positives and JE IgM-negatives). The ﬁrst 105 JE IgM-positive
specimens in the randomized list and all the JE IgM-negative
specimens listed consecutively between those positive specimens
were selected for a total of 350 study specimens for testing with
the commercial kits. Specimens (positive as well as negative) with
inadequate volume, thatweremissing from the storage site, and/or
those with indistinct NPHL ID numbers were skipped and replaced
by the subsequent positive or negative specimens in the
randomized list. The total study population selected should
therefore be representative of the normal encephalitis patient
population in Nepal in 2005.
2.2. Commercial (index) kits and reference standard
The two commercially available ELISA kits evaluated in this
study, XCyton and Panbio, are interpreted based on a qualitative
result indicating presence or absence of JE antibodies in the
sample. Both index test kits use a cell culture-derived recombinant
particulate JE antigen and, additionally, the Panbio assay uses
recombinant dengue-1 through –4 antigens. The Panbio kit has
dual antigens (JE and dengue) and the XCyton kit contains only a JE
antigen.
The reference standard for this study was the AFRIMS in-house
JE MAC ELISA performed at the AFRIMS laboratory.15 Trained and
experienced technicians tested each study sample, either initially
in 2005 as part of the routine quality control system that is in place
for Nepal’s JE surveillance system (10% of negatives and all
positives are retested with JE and dengue antigen for conﬁrmation
at AFRIMS) or if this result was not available, the sample was
retested as part of this study.
2.3. Laboratory and data management procedures
Preparation and testing of surveillance specimens are described
elsewhere.14 After receiving the selected 350 study subject
specimens from NPHL, WARUN prepared two aliquots of each
specimen. Laboratory personnel were blinded to each sample’s
reference standard result when conducting the testing with the
commercial kits.
A single, trained laboratory technician at NPHL, who was
masked to the reference standard assay results, tested each
specimen with both index kits. The technician was trained in basic
ELISA methodology and followed kit instructions based on the
product insert, and laboratory supervisors were available to
answer questions and monitor the testing. The test kits were
run singly on each sample, with retesting conducted when
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initial equivocal result). The initial testing and subsequent
retesting were each completed within a one-week period. The
technician completed a qualitative questionnaire on the usability
of the two assays after completing the laboratory testing.
Final results for each sample with the index and reference
assayswere classiﬁed as ‘JE-positive’, ‘JE-negative’ (including those
that were determined to be dengue-positive by Panbio), or
‘equivocal’ (including other suspected ﬂavivirus infections deter-
mined by XCyton), according to the manufacturers’ instructions.
All results from the two commercial assays were entered into an
Excel (Microsoft Corp., Seattle, WA, USA) database, rechecked
against source documents, such as ELISA reader printouts, to
conﬁrm accurate data entry, and double-checked by personnel at
WARUN. The samples were then unmasked (i.e., all reference
results were matched to each sample) and a master database
containing AFRIMS, Panbio, and XCyton results for each sample
was created for analysis.
2.4. Data analysis
The study results were analyzed to determine the concordance
or agreement, positive and negative predictive values, and
sensitivity and speciﬁcity (deﬁnitions given below) of each of
the two kits in relation to the AFRIMS JE IgM ELISA. For all
quantitative measures, 95% exact binomial conﬁdence intervals
(CIs) were calculated. For the purpose of this evaluation and as per
the protocol, equivocal results or ﬂavivirus unspeciﬁed (deﬁned
according to the kit instructions) from the two test kits were coded
as ‘JE-negative’ in the ﬁnal analysis. Datawere analyzed using Stata
version 9.2 (StataCorp, College Station, TX, USA). Qualitative
results from the technician’s responses to the test kit usability
questionnaire were recorded.
The positive predictive value (PPV) and negative predictive
value (NPV) are deﬁned as the probability of the subject having or
not having JE disease following a positive or a negative test result,
respectively. Predictive values are calculated using the likelihood
ratios and assume the given prevalence is correct. Sensitivity is
deﬁned as the proportion of pathogen-positive subjects correctly
identiﬁed, and speciﬁcity is the proportion of pathogen-negative
subjects correctly identiﬁed, by the test. Ameasure of concordance
or agreement between the index test results and the reference test
results is calculated along with the kappa statistic, which provides
ameasure of the reliability of a categorical variable beyond the role
of chance alone.16Table 1
Description of the study population
Characteristic Number
(% or median)
Encephalitis cases, AFRIMS IgM-positive (%) 132/350 (37.7)
Mean age in yearsa (median) 17 (12)
Malea (%) 184 (54.8)
Districts with largest proportion of casesa (% of total)
Kailali 50 (14.9)
Bardiya 49 (14.6)
Banke 38 (11.3)
Dang 32 (9.5)
Kathmandu City 30 (8.9)
Mean number of days from onset to
collectionb (median)
6.9 (5)
AFRIMS, Armed Forces Research Institute of Medical Sciences.
a 336 of 350 encephalitis cases had complete data on age, sex, and district of
residence.
b 277 of 350 encephalitis cases had complete data on dates of onset and specimen
collection.2.5. Retesting of Panbio
The laboratory results from Panbio and XCyton testing at NPHL
were analyzed for PPV and NPV, sensitivity, and speciﬁcity. The
sensitivity of the Panbio kit was found to be low and inconsistent
with that found in previous studies and evaluation settings.6 In
order to investigate the possible reasons for the low sensitivity of
this kit under the existing ﬁeld conditions, a retesting of all the 350
samples with a new batch of Panbio kits was undertaken at NPHL
and also at AFRIMS, using identical laboratory protocols. The ﬁrst
test results at NPHL are referred to hereafter as Panbio1, the second
retest results as Panbio2, and the AFRIMS retest results as Panbio3.
The results were compared to get a better understanding of
whether there was a batch or transport/storage issue with the
Panbio kit, orwhether therewere problemswith laboratory testing
processes in Nepal.
2.6. Sample size
A sample size calculation for a binomial proportion was used
where the sample size (N) depends on: the Z score (1.645 for a 90%
conﬁdence limit); expected sensitivity or speciﬁcity of the test (p);
and the desired precision of this expected proportion (L), set at 0.05.
The expected sensitivity and speciﬁcity of these test kits was
assumed to be at least 90%, and not less than 85% comparedwith the
AFRIMS reference standard (with a precision of 5%). The formula,
N = {Z2  p  (1 p)}/L2, with an estimated disease prevalence of
35%, yielded a sample size requirement of 98 JE-positives and 98 JE-
negatives. To account for error in specimen handling and processing
that occurs with any laboratory-based activity, at least 105 JE-
positive and 105 JE-negative specimens were estimated.
3. Results
3.1. Study population demographics
The demographic characteristics of the study population of 350
randomly selected AES samples from the 2005 surveillance
population are shown in Table 1. The initial sample selection
procedure used the NPHL–AFRIMS JE IgM result, which yielded 105
JE-positive samples. However, 132 of the 350 samples were JE-
seropositive according to the testing done at AFRIMS (the reference
standard for this study), giving a prevalence of 38%. None of the
study samples were positive for dengue by the AFRIMS dengue test
conducted at AFRIMS. The median age of subjects in the study was
12 years (mean 17 years), and 45% were female. The AES cases in
this study had onset dates between 20May and 17December 2005,
in effect capturing one JE transmission season spanning the
months of June through October.14 With regard to district of
residence, 59% of subjects in this study came from the four
hyperendemic western districts and the city of Kathmandu. The
average number of days from symptom onset to collection of the
samplewas 7 days (median 5 days), which is at the lower end of the
7 to 10 days recommended by the WHO.5,7
3.2. Diagnostic accuracy and kit performance characteristics
3.2.1. Initial analysis
The ﬁrst round of testing was done at NPHL with both XCyton
and Panbio kits run simultaneously on the 350 samples. For the
Panbio kit (Panbio1), PPV and NPV were 90% (95% CI 82–95%) and
85% (95% CI 79–89%), respectively; the sensitivity was 71% (95% CI
63–79%) and the speciﬁcity was 95% (95% CI 91–98%). For the
XCyton kit, the PPV and NPV were 84% (95% CI 77–90%) and 96%
(95% CI 92–98%), respectively; the sensitivity was 93% (95% CI 88–
97%) and the speciﬁcity was 89% (95% CI 85–93%).
Figure 1. Performance characteristics for JE IgM of Panbio and XCyton versus AFRIMS JE IgM ELISA reference standard.
JE, Japanese encephalitis; IgM, immunoglobulin M; AFRIMS, Armed Forces Research Institute of Medical Sciences; ELISA, enzyme-linked immunosorbent assay; PPV, positive
predictive value; NPV, negative predictive value; NPHL, National Public Health Laboratory (Nepal). Note: Error bars shown are 95% conﬁdence intervals.
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In the retest of the Panbio kit (Panbio2), undertaken because the
sensitivity of the Panbio kit in the initial analysis was inconsistent
with previous results, the sensitivity of the Panbio kit conducted at
NPHL was 80% (95% CI 72–87%) and the speciﬁcity was 97% (95% CI
94–99%). PPV and NPV for Panbio were 94% (95% CI 88–98%) and
89% (95% CI 87–93%), respectively. The results of the NPHL initial
(Panbio1) and retesting (Panbio2) with the Panbio kit, the Panbio
testing by AFRIMS (Panbio3), and the XCyton kit were compared
(Figure 1).
The cross-tabulation of the positive and negative results of the
two commercial kits, including the two sets of Panbio testing, are
shown against the AFRIMS MAC ELISA reference standard result in
Table 2. Results of the analysis of key parameters of diagnostic
performance of the two commercial kits compared to the AFRIMS
reference standard are shown in Figure 1. Overall, the concordance
or measure of agreement of the kits with the AFRIMS reference
standard was very good and the same (91%) for both XCyton and
Panbio2, but was slightly lower (86%) for Panbio1. The agreement
values corresponded to kappa statistics of 0.69 (95% CI 0.61–0.77;
p < 0.0001) for Panbio1; 0.79 (95% CI 0.73–0.86; p < 0.0001) for
Panbio2; and 0.81 (0.75–0.87; p < 0.0001) for XCyton. TheseTable 2
Cross-tabulation of AFRIMS IgM ELISA in comparison with Panbio and XCyton
results
AFRIMS
Positive Negative Total
XCyton Positive 123 23 146
Negative 9 195 204
Panbio1 Positive 94 11 105
Negative 38 207 245
Panbio2 Positive 106 7 113
Negative 26 211 237
Total 132 218 350
AFRIMS, Armed Forces Research Institute of Medical Sciences.
Note: All equivocal results were coded negative, as per protocol.statistically signiﬁcant results indicate that the agreement
between the index kits and the reference standard for Panbio
and XCyton, respectively, are not likely due to chance alone.16
3.3. Kit usability
In general, the technician’s responses to usability for each of the
two kits were very similar, particularly with regard to preparatory
steps such as additional equipment required, handling and
processing of specimens, and clarity of instructions. According
to the technician report, processing with the XCyton kit took about
4 h, with 2 h of hands-on time with 88 samples per plate (single
well for each sample). Testing with the Panbio kit was marginally
faster, taking approximately 3.25 h, with approximately 1.5 h of
hands-on time, however testing only 43 samples (two wells for
each sample for the JE and dengue antigens). No major difﬁculties
were encountered with either kit.
4. Discussion
In many countries where JE is endemic there is almost no
systematic, population-based routine surveillance for the disease.4
Where surveillance does exist, the quality of the system is variable,
depending on multiple factors, including timely care-seeking
behavior, recognition of symptoms, case ﬁnding and reporting,
sample collection at the optimal time, and perhaps most
importantly, the collection and laboratory testing of appropriate
clinical samples because of lack of test reagents. It is absolutely
essential, therefore, that easy-to-use, standardized, affordable test
kits are available in order to strengthen JE diagnostic and
surveillance capacity in resource-poor, endemic settings. This
study was the ﬁrst to do a ﬁeld evaluation of the diagnostic
performance characteristics of two relatively new commercial
diagnostic assays for JE IgM detection when used with samples
collected in a routine JE surveillance system and with testing
conducted in a national-level laboratory. In particular, this study
was able to determine the predictive values, positive and negative,
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selected from a population of AES patients reported to Nepal’s
national surveillance system. Because many JE-endemic countries
have limited capacity for collection of CSF and thus serum is the
primary sample available for JE diagnostic testing, we considered it
important to evaluate both the commercial kits using serum
samples collected during routine surveillance, even though CSF is
the preferred diagnostic sample.
Thepredictive values are indicatorsof theusefulnessof thesekits
in distinguishing patients who truly have JE from those who do not,
when the tests are utilized in applied ﬁeld settings for a given
population prevalence. The Panbio kit demonstrated very good
predictive values with Panbio1 (PPV 90% and NPV 84%) and slightly
higher predictive values with Panbio2 (PPV 94% and NPV 90%). The
XCytonkithadsimilarlygoodresultswithPPVat84%andNPVat96%
for this population, with a prevalence of 38%. Both the Panbio and
XCyton kits demonstrated excellent speciﬁcity (Panbio1: 95%;
Panbio2: 97%; XCyton: 89%). These high speciﬁcity results are
encouraging, because with the progressively more widespread
implementation of JE immunization programs, the incidence of JE
will decrease, andhigh speciﬁcity of assayswill become increasingly
important. The Panbio kit showed good sensitivity with the second
run (Panbio2: 80%), but lower sensitivity with Panbio1 (71%), and
the XCyton kit showed very good results for sensitivity (93%).
Because predictive value is affectedmainly by prevalence of disease
in the population and the speciﬁcity of the test when used in
populationswhere the disease is uncommon, in these evaluations it
remained largely unaffected by the lower sensitivity observed for
Panbio. These performance characteristics, in particular the high
predictive values, indicate that both commercial assays are useful
for JE surveillance in similar population settings.
In 2005, an evaluation of commercial JE ELISA kits was
conducted at AFRIMS with a set of pre-selected serum specimens
that were well-characterized as JE, dengue, or JE-negative speci-
mens.6 The speciﬁcity of the Panbio kit was very similar, 99% (95%
CI 97–100%) for the 2005 study compared to 95% (95% CI 91–98%)
for Panbio1 and 97% (95% CI 94–99%) for Panbio2 in the current
study. However, the sensitivity was much lower in the current
study at 71% (95% CI 63–79%) for Panbio1 and 80% (95% CI 72–87%)
for Panbio2 compared to the 2005 study at 89% (95% CI 82–94%).
The fact that the conﬁdence intervals of each of the parameter
estimates overlap indicates non-statistically signiﬁcant differ-
ences, except for the lower sensitivity for Panbio1 in the current
study compared to the same parameter in the 2005 study, which is
signiﬁcantly different (Chi-square, p < 0.0001).
With regard to the XCyton kit, sensitivity was similar in both
studies at 97% (95% CI 91–99%) and 93% (88–97%), but speciﬁcity
was vastly improved from 65% (95% CI 59–71%) in the 2005 study
to 89% (95% CI 85–93%) in the current study. This was a statistically
signiﬁcant difference (Chi-square, p < 0.001). The XCyton assay
does not include a dengue antigen and testing algorithm like the
Panbio assay. Thus, the lower speciﬁcity in 2005 was likely a result
of substantial dengue IgM cross-reactivity with the JE antigen in
the serum samples. In the current study, however, the marked
improvement in speciﬁcity was presumably because therewere no
detectable dengue antibodies in the population tested by the
AFRIMS reference assay.
The retesting of all the samples with the Panbio kit showed that
the performance characteristics of the three sets of testing
(Panbio1 and Panbio2 at NPHL and Panbio3 at AFRIMS) were
similar and the differences were not statistically signiﬁcant. This
suggests that a national laboratory such as NPHL is capable of
producing similar caliber work to a reference laboratory using a
commercial kit for JE, such as the Panbio kit. Although not
statistically signiﬁcant, differences in sensitivity were observed.
These differences could be related to laboratory and transportationfactors that were not measured in this study, including tempera-
ture control in kit transportation and storage. However, these
differences could also reﬂect lot-to-lot variability in the commer-
cial kit. These observations emphasize the importance of theWHO
JE laboratory network with lab accreditation, quality control and
proﬁciency testing to help account for such issues. In addition to
using validated kits, the network includes standardized testing
protocols, procedures for calibration of equipment and instru-
ments, and a strong laboratory quality assurance program.7
Overall, the study population was comparable to the broader
AES surveillance population.14 In a review by Wierzba and
colleagues of JE surveillance in Nepal between 2004 and 2006,
32% of AES cases with diagnostic specimens collected (3198/4652
or 69%) were IgM-positive for JE.14 This compares to a slightly
higher ﬁgure of 38% in this study population. Just over half (52%) of
the AES cases in this study came from the four western
hyperendemic Terai districts, whereas 44% of the 2004 to 2006
AES surveillance cases with specimens were from these four
districts. Of those cases, the mean age was 18 years, and 43% were
female.14 The population in this study was comparable, with a
mean age of 17 years and 45% females. It should however be noted
that approximately twice as many JE cases were detected during
the 2005 season (n = 664) than the one in 2004 (n = 371),14 which
could reﬂect increased case detection or normal seasonal
variability in JE cases.
A strengthof this study is that it useda largenumber of randomly
selected samples from clinically-diagnosed encephalitis cases
within a national AES surveillance system. These samples were
from Nepal’s fully-functional population- and hospital-based
surveillance system for AES, which has covered more than 24
endemic districts since 2004.13,14 This study also evaluated the
capabilities of a national laboratory (NPHL) compared to a reference
laboratory (AFRIMS) in the use of commercial kits for JE (Panbio2
compared to Panbio3). In addition, the reference standard – the
AFRIMS JE ELISA kit – was selected because it had been used in
previous evaluations of the same commercial kits and could
therefore provide a measure of comparability to prior evaluations.6
The JE surveillance system in Nepal is very strong and one of the
best models of JE surveillance in a developing, JE-endemic country.
The system does have some limitations for this studywhich should
be noted. WHO surveillance standards support the diagnosis of JE
in AES from a single serum sample, and in Nepal mostly single
serum samples are collected for diagnosis. However, one-third of
AES cases do not have a sample collected. Frequently, the sample is
collected early in the course of illness, without a second
convalescent sample collected. Samples, including those that are
JE-negative, are not routinely tested for other etiologies.14 WHO
standards recommend that if an initial serum specimen is negative,
a further sample should be taken 7 to 10 days following onset to
allow antibodies to rise to a detectable level.
Dengue virus circulation has not been reported extensively in
Nepal, and no dengue IgM was detected in the samples from 2005
tested in our study, whereas many countries endemic for JE have
co-circulating dengue virus.17 Thus a limitation of our study is that
the AES population is not necessarily representative of populations
in other countries in the Asia-Paciﬁc region. Another limitation is
that the AFRIMS reference testing in many cases was conducted
earlier than the study evaluation of the commercial kits, so there is
a possibility that antibody could have degraded during sample
storage. However, this is unlikely as good storage conditions were
maintained in the interval between AFRIMS testing and the study
testing.
The performance characteristics of the Panbio and XCyton JE
kits in this evaluation suggest that these kits could be considered
acceptable in routine JE diagnostic testing in a similar patient
population. To better understand the impact of dengue virus
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commercial kits, it would be useful to conduct additional studies in
a country in Asia where both JE and dengue are endemic. Further
evaluation of the usability of the kits from additional laboratory
technicians would be helpful in establishing functionality of these
commercial kits. In settings with signiﬁcant dengue co-circulation,
false-positive results could be obtained. This is programmatically
of low signiﬁcance in routine surveillance before JE vaccination,
but as JE vaccination becomes standard practice, false-positive
results could give an erroneous indication of vaccine failure. After
JE vaccine introduction, samples collected for case conﬁrmation in
JE surveillance should be CSF, which, unlike serum, does not have
antibody after immunization. XCyton recommends the use of their
kit on CSF, especially where dengue is co-endemic, and both kits
recommend conﬁrmatory testing with plaque-reduction neutra-
lizing testing.
In summary, both commercial kits performed well in this ﬁeld
evaluation in a JE-endemic area with limited dengue virus
circulation. PPV, NPV, sensitivity, and speciﬁcity values demon-
strated generally good performance characteristics for diagnostic
accuracy, indicating that the two kits would perform reasonably
well within national surveillance systems for detection of JE among
encephalitis cases. Additional evaluation in other JE-endemic areas
where there are high rates of dengue virus transmission would be
valuable. The results of this study provide important information
that will assist with designing laboratory-based surveillance
systems for JE and help facilitate ascertainment of JE disease
incidence in endemic populations. Population-based surveillance
for JE that enables understanding of disease burden and
epidemiological patterns is an important contributing factor in
national-level decision-making on the introduction of JE vaccine.
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